CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...